We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Integumen Plc | LSE:SKIN | London | Ordinary Share | GB00BMGWZY29 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 28.00 | 28.00 | 29.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMSKIN
RNS Number : 6637D
Integumen PLC
11 October 2018
11 October 2018
Integumen plc
("Integumen" or "the Company")
Update on Placing and Subscription
The Company provides an update further to the announcement of 27 September 2018.
Funding
As announced on 27 September 2018 the Company has been provided with access to working capital from an unsecured loan facility provided by Cellulac plc with an interest rate of 0% on funds drawn.
It has been agreed in principle by Integumen and Cellulac, that this zero-interest facility is being extended until 30 April 2019 by up to an additional GBP300,000. Along with funds already loaned to Integumen, the total amount is not expected to exceed GBP400,000. Further amounts drawn down under the facility will be subject to the same conditions. The funds drawn under this arrangement will not fall as repayable until completion of an alternative funding arrangement or completion of any corporate transaction requiring Integumen shareholders' approval under AIM Rule 14. The Directors intend to draw on the facility as required to meet the Company's ongoing working capital needs.
The above non-dilutive funding facility is taking the place of the second tranches of the Placing and Subscription (previously announced on 16 July 2018, 19 July 2018 and 24 July 2018) which will not now proceed.
Investment in Cellulac
It is expected that completion of Integumen's acquisition of a 9.35% stake in Cellulac plc will take place shortly. Further details will be notified in due course.
Hot Features
Premium
Gerard Brandon, Chief
Integumen plc Executive +44 (0) 1223 926 660
SPARK Advisory Partners
Limited Neil Baldwin/Andrew
(Nominated Adviser) Emmott +44 (0) 113 370 8974
----------------------- ---------------------
Hybridan LLP (Broker) Claire Noyce +44 (0) 20 3764 2341
----------------------- ---------------------
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
UPDEAPEEFDFPFFF
(END) Dow Jones Newswires
October 11, 2018 02:00 ET (06:00 GMT)
1 Year Integumen Chart |
1 Month Integumen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
